EpiPens are the poster child for vast increases in the price of familiar medications. Many people carry them for emergency treatment of allergic reactions that can be life threatening. So, when the Mylan Company raised the price of two EpiPens from $100 $614 it made big news. Turns out, it's the tip of the iceberg. Drug prices are on the rise and desperately ill people are often those hit by bills they never expected. Other countries have established price controls for life-or-death medications, but America's system is so complex it defies understanding. Drug and insurance companies, hospitals and doctors engage in secret negotiations, while various middlemen get cuts of the action. And, who's paying for those expensive ads on TV? Patients. Are the presidential campaigns offering any realistic solutions?
Can politics cure the high cost of drugs?
Katie Thomas - New York Times reporter covering health care and the drug industry - @katie_thomas, Erin Fox - University of Utah Health Care - @foxerinr, Thomas Stossel - Brigham and Women's Hospital - @tstossel4, Timothy McBride - Washington University - @mcbridetd